WO1999001573A3 - Verfahren und testkit zum nachweis bösartiger tumore - Google Patents

Verfahren und testkit zum nachweis bösartiger tumore Download PDF

Info

Publication number
WO1999001573A3
WO1999001573A3 PCT/DE1998/001806 DE9801806W WO9901573A3 WO 1999001573 A3 WO1999001573 A3 WO 1999001573A3 DE 9801806 W DE9801806 W DE 9801806W WO 9901573 A3 WO9901573 A3 WO 9901573A3
Authority
WO
WIPO (PCT)
Prior art keywords
test kit
bax
cell lines
malignant tumours
amplifying
Prior art date
Application number
PCT/DE1998/001806
Other languages
English (en)
French (fr)
Other versions
WO1999001573A2 (de
Inventor
Timo Hillebrand
Bernd Doerken
Gerhard Wolff
Peter Bendzko
Original Assignee
Invitek Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Invitek Gmbh filed Critical Invitek Gmbh
Priority to AU90610/98A priority Critical patent/AU9061098A/en
Priority to EP98942468A priority patent/EP0991780A2/de
Publication of WO1999001573A2 publication Critical patent/WO1999001573A2/de
Publication of WO1999001573A3 publication Critical patent/WO1999001573A3/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Die Erfindung betrifft ein Verfahren zum Nachweis von Mutationen des Bax-Genes in Tumoren unter Verwendung nichtradioaktiver Techniken sowie einen entsprechenden Testkit, der 1) DNA oder RNA Extraktionsmodul, 2) Primermix (mit einem Hex-markierten Primer), 3) Kontrollzellinien-DNA zur Amplifikation der Bax-Wildtypsequenz, 4) Kontrollzellinien-DNA zur Amplifikation von mutiertem Bax, 5) Fragmentlängenstandard (Rox-markierte Fragmentleiter) enthält.
PCT/DE1998/001806 1997-07-01 1998-07-01 Verfahren und testkit zum nachweis bösartiger tumore WO1999001573A2 (de)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU90610/98A AU9061098A (en) 1997-07-01 1998-07-01 Method and test kit for detecting malignant tumours
EP98942468A EP0991780A2 (de) 1997-07-01 1998-07-01 Verfahren und testkit zum nachweis bösartiger tumore

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19727932A DE19727932A1 (de) 1997-07-01 1997-07-01 Verfahren und Testkit zum Nachweis bösartiger Tumore
DE19727932.5 1997-07-01

Publications (2)

Publication Number Publication Date
WO1999001573A2 WO1999001573A2 (de) 1999-01-14
WO1999001573A3 true WO1999001573A3 (de) 1999-04-01

Family

ID=7834219

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE1998/001806 WO1999001573A2 (de) 1997-07-01 1998-07-01 Verfahren und testkit zum nachweis bösartiger tumore

Country Status (4)

Country Link
EP (1) EP0991780A2 (de)
AU (1) AU9061098A (de)
DE (1) DE19727932A1 (de)
WO (1) WO1999001573A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2615143C2 (ru) 2010-03-24 2017-04-04 Адвирна Самодоставляющие PHKi соединения уменьшенного размера
US10934550B2 (en) 2013-12-02 2021-03-02 Phio Pharmaceuticals Corp. Immunotherapy of cancer
CA2947270A1 (en) 2014-04-28 2015-11-05 Rxi Pharmaceuticals Corporation Methods for treating cancer using nucleic acids targeting mdm2 or mycn

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19736715A1 (de) * 1996-08-17 1998-02-19 Invitek Gmbh Mittel und seine Verwendung zur komplexen molekularen Tumordiagnostik

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19736715A1 (de) * 1996-08-17 1998-02-19 Invitek Gmbh Mittel und seine Verwendung zur komplexen molekularen Tumordiagnostik

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
ANTICANCER RESEARCH, (1998 MAY-JUN) 18 (3A) 1655-9. JOURNAL CODE: 59L. ISSN: 0250-7005., Greece *
BLOOD, (1998 APR 15) 91 (8) 2991-7. JOURNAL CODE: A8G. ISSN: 0006-4971., United States *
DATABASE BIOSIS BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; BARGOU, RALF C. (1) ET AL: "Expression of the bcl-2 gene family in normal and malignant breast tissue Low bax -alpha expression in tumor cells correlates with resistance towards apoptosis.", XP002092314 *
DATABASE BIOSIS BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; BARGOU, RALF C. ET AL: "Overexpression of the death-promoting gene bax -alpha which is downregulated in breast cancer restores sensitivity to different apoptoti stimuli and reduces tumor growth in SCID mice.", XP002092313 *
DATABASE MEDLINE US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; BILIM V N ET AL: "Absence of frameshift mutations in the bax gene in renal cell cancer (RCC) and transitional cell cancer (TCC).", XP002092316 *
DATABASE MEDLINE US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; CHUNG Y J ET AL: "Evidence of genetic progression in human gastric carcinomas with microsatellite instability.", XP002092317 *
DATABASE MEDLINE US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; MEIJERINK J P ET AL: "Hematopoietic malignancies demonstrate loss-of-function mutations of BAX.", XP002092315 *
INTERNATIONAL JOURNAL OF CANCER, (1995) VOL. 60, NO. 6, PP. 854-859. ISSN: 0020-7136. *
JOURNAL OF CLINICAL INVESTIGATION, (1996) VOL. 97, NO. 11, PP. 2651-2659. ISSN: 0021-9738. *
ONCOGENE, (1997 OCT 2) 15 (14) 1719-26. JOURNAL CODE: ONC. ISSN: 0950-9232., ENGLAND: United Kingdom *
RAMPINO ET AL.: "Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype", SCIENCE, vol. 275, 14 February 1997 (1997-02-14), pages 967 - 969, XP002092054 *
ZIEGLE J S ET AL: "APPLICATION OF AUTOMATED DNA SIZING TECHNOLOGY FOR GENOTYPING MICROSATELLITE LOCI", GENOMICS, vol. 14, no. 4, December 1992 (1992-12-01), pages 1026 - 1031, XP000610563 *

Also Published As

Publication number Publication date
EP0991780A2 (de) 2000-04-12
DE19727932A1 (de) 1999-01-07
AU9061098A (en) 1999-01-25
WO1999001573A2 (de) 1999-01-14

Similar Documents

Publication Publication Date Title
WO2000053804A3 (en) Genetic screening
WO1998030883A3 (en) Analysis of genetic polymorphisms and gene copy number
IL134537A0 (en) Nucleic acid encoding an april ligand or a fragment thereof, vectors and host cells containing the same and methods for the production thereof
WO2000012726A3 (en) Rationally designed heparinases derived from heparinase i and ii
ATE336591T1 (de) Nachweisverfahren für kurze sequenzvarianten
WO1997005248A3 (en) Solution containing chaotropic agent and process using it for isolation of dna, rna and proteins
EP1034302A4 (de) De novo oder "universaler" sequenzierungs-array
DE3578190D1 (de) Test fuer nukleinsaeuresequenzen, insbesondere genetische veraenderungen.
WO2001016378A3 (en) Chromosome-wide analysis of protein-dna interactions
WO2000024929A3 (de) Über lineare amplifikation vermittelte pcr (=lam pcr)
EP0639647A3 (de) Verfahren zum Nachweis Nukleinsäure-Sequenzen.
WO1999029903A3 (en) Cancer susceptibility mutations of brca1
WO2001075175A8 (en) Manganese superoxide dismutase gene polymorphism for predicting cancer susceptibility
WO1999028506A3 (en) Cancer susceptibility mutations of brca2
EP1090294A4 (de) Verfahren um die anwesenheit von krebs in einer probe zu bestimmen durch nachweis der expression eines ssx-gens und peptiden, die von ssx oder ny-eso-1 abgeleitet sind
WO1999067382A3 (en) Angiopoietin-like growth factor sequences
ATE321138T1 (de) Polyketide, ihre herstellung, und darin benutzte materialien
DK359486D0 (da) Overfoerbare pattedyrgener forbundet med tumormetastase, fremg. til isolering deraf, proteiner som generne koder for, antistoffer over for disse, sonder for generne og for mrna transkriberet derfra og fremg. til bedoemmelse af tumorers metastatiske tilboejelighed
WO1999001573A3 (de) Verfahren und testkit zum nachweis bösartiger tumore
WO2004090547A3 (en) Metastatic colorectal cancer signatures
WO1997042343A3 (en) Teichoic acid enzymes and assays
WO2002031198A3 (en) Cancer-linked genes as targets for chemotherapy
EP0226288A3 (de) Mittel und Verfahren zur Bestimmung von Cystic Fibrosis beruhend auf genetischer Kopplung
IL126257A0 (en) Immuno-magnetic cell separation used in identification of genes associated with site-preferenced cancer metastasis formation
EP1006357A3 (de) Markerprobe, Verfahren und Vorrichtung für die Elektrophorese

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP RU

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1998942468

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1999506111

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 1998942468

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1998942468

Country of ref document: EP